Across neuroscience, a growing focus is emerging around not just protecting the brain, but actively restoring and reshaping it after injury and disease. Recent studies highlight how targeted interventions at the cellular and molecular level can influence recovery in very different conditions, from spinal cord injury to stroke to Alzheimer’s disease. Together, they reflect a shift toward precision strategies that either rebuild damaged neural circuits, prevent cell death, or alter the underlying biology driving degeneration.
One study demonstrates how spermatogonial stem cells can be converted into functional spinal neurons that survive, integrate, and improve motor recovery after spinal cord injury. Another shows that delivering mitochondrial circular RNA through extracellular vesicles can protect brain tissue after stroke by blocking ferroptosis, reducing damage and improving outcomes. A third explores how a selective G9a inhibitor can modify disease progression in Alzheimer’s by reducing toxic protein buildup and improving cognitive function. Taken together, these findings point toward a future where regeneration, protection, and epigenetic control are combined to meaningfully change the trajectory of central nervous system disorders.
1. An Optimized Conversion of Spermatogonial Stem Cells Into Spinal Cord Neurons Enhances Functional Recovery in Rats After Spinal Cord Injury
A novel cell-conversion strategy transforms spermatogonial stem cells into spinal neurons, boosting survival and integration even in inflammatory environments. Transplanted cells improved motor and sensory recovery in spinal cord injury models—positioning targeted cell reprogramming as a promising path for neural repair.
2. Extracellular Vesicle-Mediated Delivery of Mitochondrial Circular RNA MTCO2 Protects against Cerebral Ischemia by Modulating mPTP-Dependent Ferroptosis
A targeted RNA delivery approach helped protect brain cells after stroke by blocking ferroptosis, a harmful form of cell death tied to oxidative stress. In mouse models, it reduced brain injury and improved neurological recovery—pointing to a precise new strategy for neuroprotection.
3. First-in-class SAM-competitive G9a inhibitor FLAV-27 as a disease-modifying therapy for Alzheimer disease
A highly selective G9a inhibitor, FLAV-27, reduced amyloid and tau-related damage while improving memory, synaptic health, and key Alzheimer’s markers in preclinical models. The findings position epigenetic reprogramming as a promising strategy for slowing disease progression.
If you’d like to stay informed of the latest publications and breakthroughs in neuron regeneration, join our email newsletter to the right (or below on mobile). We send out weekly updates with the latest papers and studies, as well as podcast episodes with the people driving Neuroregenerative breakthroughs.
